We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bloom Energy Corporation (BE - Free Report) ) generates and distributes renewable energy.Over the past 90 days, the Zacks Consensus Estimate for BE's full-year earnings has moved 79.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. In the second quarter of 2025, Bloom Energy Corporation’s product and service revenues rose 25.9% year over year. Bloom Energy’s total revenues surged 19.5% year over year. The growth was fueled by robust demand for Bloom Energy’s solid oxide fuel cell systems and expanding adoption of hydrogen-capable solutions. The upcoming earnings release of Bloom Energy will be of great interest to investors. The company is predicted to post an EPS indicating 800% growth compared to the equivalent quarter last year. Based on the most recent data, BE has returned 306.5% so far this year.
Eli Lilly and Company (LLY - Free Report) ), one of the world’s largest pharmaceutical companies, boasts a diversified product profile, including a solid lineup of new successful drugs.Demand for Lilly’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Launches of these drugs in new international markets and improved supply from ramped-up production led to strong sales in the first half of 2025. Lilly’s other new drugs, like Kisunla, Omvoh and Jaypirca, are also contributing to its top-line growth. Lilly is also making rapid pipeline progress in obesity and diabetes. Shares of this drugmaker have returned +14.4% over the past month. For the current quarter, Lilly is expected to post earnings indicating a change of +441.5% from the year-ago quarter. Over the last four quarters, Lilly surpassed consensus EPS estimates two times. The company topped consensus revenue estimates three times over this period.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Top Stock Picks for Week of October 6, 2025
Bloom Energy Corporation (BE - Free Report) ) generates and distributes renewable energy.Over the past 90 days, the Zacks Consensus Estimate for BE's full-year earnings has moved 79.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. In the second quarter of 2025, Bloom Energy Corporation’s product and service revenues rose 25.9% year over year. Bloom Energy’s total revenues surged 19.5% year over year. The growth was fueled by robust demand for Bloom Energy’s solid oxide fuel cell systems and expanding adoption of hydrogen-capable solutions. The upcoming earnings release of Bloom Energy will be of great interest to investors. The company is predicted to post an EPS indicating 800% growth compared to the equivalent quarter last year. Based on the most recent data, BE has returned 306.5% so far this year.
Eli Lilly and Company (LLY - Free Report) ), one of the world’s largest pharmaceutical companies, boasts a diversified product profile, including a solid lineup of new successful drugs.Demand for Lilly’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Launches of these drugs in new international markets and improved supply from ramped-up production led to strong sales in the first half of 2025. Lilly’s other new drugs, like Kisunla, Omvoh and Jaypirca, are also contributing to its top-line growth. Lilly is also making rapid pipeline progress in obesity and diabetes. Shares of this drugmaker have returned +14.4% over the past month. For the current quarter, Lilly is expected to post earnings indicating a change of +441.5% from the year-ago quarter. Over the last four quarters, Lilly surpassed consensus EPS estimates two times. The company topped consensus revenue estimates three times over this period.